+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 31 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of frexalimab compared to tacrolimus in adults undergoing their first kidney transplant who have a low to moderate risk of organ rejection. This open-label, randomized study will span up to approximately 5 years, aiming to understand how these treatments perform in kidney transplant recipients. The study is sponsored by Sanofi and involves adults aged 18 to 70 years. Participants will receive either frexalimab or tacrolimus as part of their immunosuppressive therapy. The initial dose of frexalimab is given intravenously, followed by subcutaneous doses administered using an on-body delivery system. Tacrolimus is given orally as capsules. The study includes about 38 visits over the treatment period, which may extend up to 5 years. During the study, participants will be regularly monitored through various assessments including kidney function tests, measurement of rejection episodes, antibody levels, and side effects related to immunosuppressive therapy. Researchers will track outcomes such as graft survival, participant survival, kidney filtration rates, and cardiovascular events over time. Safety and drug levels will also be closely observed throughout the study duration.

Age: 18Years - 70YearsAll GendersPhase 2Phase 3
73 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating the use of semaglutide, a GLP-1 receptor agonist, for treating moderate to severe alcohol use disorder AUD in Veterans. This phase 3 randomized, double-blind, placebo-controlled trial aims to assess the effectiveness and safety of semaglutide compared to placebo. The study addresses the urgent need for new treatments for AUD, especially given the limited success of existing medications and low treatment rates among Veterans. Participants will receive weekly subcutaneous injections of either semaglutide or a placebo for 24 weeks. Semaglutide dosing starts at 0.25 mg for the first four weeks and is gradually increased up to 2.4 mg weekly, based on tolerance. Dose adjustments may slow or reduce to ensure comfort and adherence. Following treatment, there is a 4-week safety assessment period. The trial includes a total of 622 Veterans randomly assigned to either group. During the study, participants will undergo regular assessments including interviews to track daily alcohol consumption using a calendar-based method Timeline Follow-Back. Researchers will evaluate reductions in risky drinking and monitor adverse events. Additional assessments cover quality of life, psychiatric symptoms, alcohol cravings, and healthcare use. The study lasts approximately 32 months for recruitment and intervention, with follow-up and data analysis continuing until 2030.

Age: 18Years - 80YearsAll GendersPhase 3
19 locations
T

Actively Recruiting

Researchers are evaluating whether adding Osteopathic Manipulative Therapy OMT to the usual medical care provided at the VA improves treatment outcomes for individuals with chronic low back pain CLBP. This study focuses on understanding the effects of OMT, a hands-on technique involving muscle and joint movements like stretching, gentle pressure, and resistance, when combined with standard care. The trial aims to explore treatment effects such as effect sizes to inform future care approaches for CLBP. Participants will be randomly assigned to receive either usual VA care alone or usual VA care plus OMT. Usual care includes medical history review, physical exams, and possible additional tests or treatments by VA physiatrists. The OMT treatment involves physicians using hands-on techniques to move muscles and joints during the usual care visits. Participants may be asked to change positions while receiving OMT, which is provided by VA physicians involved in the study. During the study, participants will be assessed at baseline, 12 weeks, and 24 weeks for pain intensity specific to low back pain, along with other measures like general pain, activity enjoyment, anxiety, depression, sleep duration, healthcare costs, and patient impressions of change. Various questionnaires and scales will be used to track these outcomes. The study will monitor participants responses over time to evaluate the added impact of OMT alongside usual care. The trial is expected to run until August 2027.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
P

Actively Recruiting

Researchers are evaluating treatment options for patients newly diagnosed with multiple myeloma who are considered frail or intermediate-fit and who are not candidates for stem cell transplant. This phase III trial compares three different three-drug induction regimens followed by either single or double drug maintenance therapies. The study aims to find which drug combination best controls the cancer and improves patient outcomes while considering patients age, other health conditions, and physical function. Participants are randomly assigned to one of three treatment arms. In Arm 1, patients receive bortezomib, lenalidomide, and dexamethasone with bortezomib given subcutaneously and the others taken orally for up to 9 cycles, followed by lenalidomide maintenance. Arm 2 involves daratumumab with hyaluronidase-fihj given subcutaneously, lenalidomide, and dexamethasone for induction, followed by lenalidomide maintenance. Arm 3 includes the same induction as Arm 2, but maintenance therapy combines daratumumab with hyaluronidase-fihj and lenalidomide. Each cycle lasts 28 days, and treatment continues without disease progression or unacceptable side effects. During the trial, participants undergo regular assessments including tumor measurements, blood tests, and quality-of-life questionnaires. Researchers monitor progression-free survival, overall survival, response rates, minimal residual disease status, and patient-reported symptoms and health status. After completing treatment, patients are followed up every 3 months for one year, every 6 months for two years, and then annually for up to 10 years to monitor long-term outcomes and safety.

All AgesAll GendersPhase 3
397 locations
P

Actively Recruiting

Researchers are evaluating combinations of targeted drugs in people with advanced non-small cell lung cancer that has spread and shows specific changes in the EGFR and MET genes. This phase II Lung-MAP trial focuses on patients whose cancer has progressed after treatment with osimertinib and aims to compare the effectiveness of combining capmatinib, osimertinib, and ramucirumab. The study also investigates safety, response rates, and survival outcomes while collecting biological samples for further analysis. Participants are randomly assigned to one of two groups. One group receives capmatinib and osimertinib as oral medications plus ramucirumab given intravenously, while the other group receives only capmatinib and osimertinib orally. During the trial, patients undergo regular CT or MRI scans and blood sample collections to monitor their disease and treatment effects. The study includes detailed assessments of tumor responses and side effects over time. Throughout the trial, participants will have scans and blood tests at scheduled intervals to assess disease progression and treatment impact. Researchers will monitor progression-free survival as the main outcome, along with response duration and toxicity. Blood samples are also collected to study circulating tumor DNA. The study continues up to three years, with ongoing safety and efficacy evaluations. Participants must meet specific health criteria and provide informed consent before joining.

Age: 18Years +All GendersPhase 2
454 locations
R

Actively Recruiting

Researchers are evaluating the safety and effectiveness of combining ASTX727 and venetoclax with or without enasidenib in treating older adults newly diagnosed with acute myeloid leukemia AML who have a mutation in the IDH2 gene. This phase II trial aims to see if adding enasidenib to the usual treatment can improve outcomes by reducing measurable residual disease-negative complete remission rates in patients who are either older or unfit for standard therapy. Participants are randomly assigned to one of two treatment groups. One group receives oral ASTX727 daily on days 1-5 and venetoclax daily on days 1-28 of each 28-day cycle. The other group receives the same treatment plus oral enasidenib daily on days 1-28. Treatment cycles continue every 28 days unless disease progression or unacceptable side effects occur. Throughout the trial, blood samples, bone marrow aspirations, and biopsies are collected to monitor disease and treatment effects. During the study, participants undergo regular evaluations including blood tests and bone marrow procedures to assess remission status and measurable residual disease. After completing treatment, participants are followed monthly for the first year, then every two months in the second year, every three months in the third year, and every six months up to five years or until death. Researchers measure remission rates, survival outcomes, and adverse events to understand the treatments impact on AML with IDH2 mutation.

Age: 18Years +All GendersPhase 2
138 locations
G

Actively Recruiting

Researchers are evaluating the addition of nutritional support to the standard care for veterans aged 60 and older who have been hospitalized with new or worsening chronic heart failure. This study compares the effects of providing home-delivered, low-sodium, nutritionally complete meals and extra dietary counseling against the standard of care, which includes standardized dietary education and one counseling session after hospital discharge. Participants are randomly assigned to one of two groups one receives only the standard dietary care, and the other receives home-delivered meals for six weeks plus three remote dietary counseling sessions alongside the standard care. This study is double-blinded and conducted across multiple centers to assess supportive care methods in heart failure management. During the study, participants will be monitored for outcomes including days alive out of the hospital and changes in health-related quality of life within six weeks after discharge. Additional evaluation of days alive out of the hospital at six months post-discharge will also be conducted. Participants will engage in dietary counseling and meal consumption with follow-up assessments to evaluate clinical benefits and quality of life over the study period.

Age: 60Years +All GendersPhase Not Applicable
21 locations
S

Actively Recruiting

Researchers are investigating the use of empagliflozin, a type of SGLT2 inhibitor, in Veterans who have received kidney transplants and have chronic kidney disease CKD, with or without type 2 diabetes mellitus T2DM. Although kidney transplantation improves health and quality of life, long-term outcomes remain challenging due to a high risk of cardiovascular disease and graft loss. Previous studies showed benefits of SGLT2 inhibitors in CKD patients but excluded kidney transplant recipients due to safety concerns. This trial aims to assess the safety and effects of empagliflozin in this specific population. This open-label clinical trial will treat eligible kidney transplant recipients with empagliflozin 12.5 mg once daily. The study is conducted at multiple VA medical centers with expertise in transplant and diabetes care. Researchers will closely monitor participants for adverse events and any effects on graft function or diabetes management. Data from non-treated kidney transplant recipients will be used for comparison to further evaluate cardiovascular outcomes, kidney disease progression, and healthcare costs associated with empagliflozin use. Participants will be followed for about two years, during which researchers will assess discontinuation of empagliflozin and monitor infections, hypoglycemia, major cardiac and kidney events, graft dysfunction, rejection episodes, and other safety concerns. Laboratory tests, kidney biopsies, and assessments of kidney function, blood sugar control, body weight, and blood pressure will also be performed. The study aims to provide important safety and feasibility data to improve care for kidney transplant recipients.

Age: 19Years +All GendersPhase 4
5 locations
T

Actively Recruiting

Researchers are studying Veterans with mental health and substance use disorders who are at risk of unemployment, which can negatively impact their health and well-being. The trial evaluates a new vocational counseling program called Purposeful Pathways added to the standard Transitional Work TW program, aiming to improve employment and quality of life. This phase II, multi-site randomized controlled trial compares Purposeful Pathways plus TW to TW alone among Veterans at three VA sites. Participants receive either TW alone or TW combined with the Purposeful Pathways intervention, which is a manualized counseling program delivered weekly for up to 12 sessions over 12 weeks. Purposeful Pathways focuses on career exploration, goal setting, job-search skills, and self-regulation, provided in person or via telehealth. TW offers immediate access to non-competitive paid jobs within or near VA hospitals, staffed by vocational rehabilitation specialists. Throughout the study, Veterans complete surveys assessing employment status, hours worked, income, career adaptability, meaningful work, quality of life, mental health symptoms, and substance use. Some participants in the intervention group may also take part in exit interviews about their experience. Researchers will measure outcomes through about 15 months of follow-up, tracking employment and other health and social factors to evaluate the effectiveness of adding Purposeful Pathways to TW.

Age: 18Years +All GendersPhase Not Applicable
3 locations

1-10 of 31

1